Dynavax Technologies Stock Today

DVAX Stock  USD 11.28  0.06  0.53%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 20

 
High
 
Low
Low
Dynavax Technologies is trading at 11.28 as of the 20th of June 2024; that is -0.53 percent decrease since the beginning of the trading day. The stock's open price was 11.34. Dynavax Technologies has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Dynavax Technologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of April 2024 and ending today, the 20th of June 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
19th of February 2004
Category
Healthcare
Classification
Health Care
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Dynavax Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 130.89 M outstanding shares of which 21.39 M shares are currently shorted by private and institutional investors with about 9.19 trading days to cover. More on Dynavax Technologies

Moving against Dynavax Stock

  0.67HCM HUTCHMED DRCPairCorr
  0.5PMVP Pmv PharmaceuticalsPairCorr
  0.49ACRV Acrivon TherapeuticsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Dynavax Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business PresidentRiccardo Manetti
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ Composite, NASDAQ Composite Total, Pharmaceutical Products, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.150.233
Way Down
Slightly volatile
Total Current Liabilities58.2 M62.2 M
Notably Down
Slightly volatile
Non Current Liabilities Total328.5 M312.8 M
Sufficiently Up
Slightly volatile
Total AssetsB997.1 M
Sufficiently Up
Slightly volatile
Total Current Assets902.1 M859.1 M
Sufficiently Up
Slightly volatile
Dynavax Technologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dynavax Technologies' financial leverage. It provides some insight into what part of Dynavax Technologies' total assets is financed by creditors.
Liquidity
Dynavax Technologies currently holds 256.91 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Dynavax Technologies has a current ratio of 2.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Dynavax Technologies' use of debt, we should always consider it together with its cash and equity.

Other Non Cash Items

770,000
Dynavax Technologies (DVAX) is traded on NASDAQ Exchange in USA. It is located in 2100 Powell Street, EmeryVille, CA, United States, 94608 and employs 408 people. Dynavax Technologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.48 B. Dynavax Technologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 130.89 M outstanding shares of which 21.39 M shares are currently shorted by private and institutional investors with about 9.19 trading days to cover. Dynavax Technologies currently holds about 518.17 M in cash with 100.56 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.1.
Check Dynavax Technologies Probability Of Bankruptcy
Ownership Allocation
The majority of Dynavax Technologies outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dynavax Technologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dynavax Technologies. Please pay attention to any change in the institutional holdings of Dynavax Technologies as this could imply that something significant has changed or is about to change at the company.
Check Dynavax Ownership Details

Dynavax Stock Institutional Holders

InstituionRecorded OnShares
First Trust Advisors L.p.2024-03-31
2.8 M
Morgan Stanley - Brokerage Accounts2024-03-31
2.6 M
Renaissance Technologies Corp2024-03-31
2.4 M
Blair William & Co2024-03-31
2.4 M
Rock Springs Capital Management Lp2024-03-31
1.7 M
Fisher Asset Management, Llc2024-03-31
1.4 M
Woodline Partners Lp2024-03-31
1.4 M
Northern Trust Corp2024-03-31
1.4 M
Great Point Partners Llc2024-03-31
1.3 M
Blackrock Inc2024-03-31
23.2 M
State Street Corporation2024-03-31
10.6 M
View Dynavax Technologies Diagnostics

Dynavax Technologies Historical Income Statement

At this time, Dynavax Technologies' Net Income From Continuing Ops is fairly stable compared to the past year. Non Operating Income Net Other is likely to rise to about 9.3 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 4.1 M in 2024. View More Fundamentals

Dynavax Stock Against Markets

Dynavax Technologies Corporate Management

David NovackSr. VP of Operations and QualityProfile
Eric FringsSite VPProfile
Donn CasaleChief OfficerProfile
Nicole ArndtSr RelationsProfile

Additional Tools for Dynavax Stock Analysis

When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.